Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer

Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer

Abstract KRAS is a small GTPase family protein that relays extracellular growth signals to cell nucleus. KRASG12C mutations lead to constitutive proliferation signaling and are prevalent across human cancers. ASP2453 is a novel, highly potent, and selective inhibitor of KRASG12C. Although preclinica...

Full description

Bibliographic Details
Main Authors: Hiroyuki Sayama, Diana Marcantonio, Takeyuki Nagashima, Masashi Shimazaki, Tsuyoshi Minematsu, Joshua F Apgar, John M. Burke, Lucia Wille, Yasuhisa Nagasaka, Daniel C. Kirouac
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12661

Internet

https://doi.org/10.1002/psp4.12661

Similar Items